Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients

van Campenhout, M.; Brouwer, W.; van Oord, G.; Xie, Q.; Zhang, Q.; Zhang, N.; Guo, S.; Tabak, Ömer; Streinu-Cercel, A.; Wang, J.; Pas, S.; Sonneveld, M.; de Knegt, R.; Boonstra, A.; Hansen, B.; Janssen, H.

doi:10.1016/j.cmi.2016.02.002

Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients

Atıf İçin Kopyala

van Campenhout M. J. H., Brouwer W. P., van Oord G. W., Xie Q., Zhang Q., Zhang N., ...Daha Fazla

CLINICAL MICROBIOLOGY AND INFECTION, cilt.22, sa.6, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 6
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.cmi.2016.02.002
Dergi Adı: CLINICAL MICROBIOLOGY AND INFECTION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
İstanbul Üniversitesi Adresli: Evet

Özet

Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p <0.001; PEG-IFN add-on: -3.16 vs. -1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: -2.60 vs. -1.74 log U/mL, p <0.001; PEG-IFN addon: -2.38 vs. -2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg). (C) 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.